Learning Objectives
- Evaluate uncommon thoracic malignancies relevant to lung cancer practice, including mesothelioma, large cell neuroendocrine carcinoma, and thymic epithelial tumors.
- Explore emerging innovations in lung cancer management, with a focus on robotic-assisted surgery, stereotactic body radiation therapy (SBRT), and the clinical application of antibody-drug conjugates (ADCs).
- Analyze recent advances and evolving standards of care in HER2-driven and other molecular subtypes of lung cancer, emphasizing personalized treatment approaches.
Co-Chairs
Dr. Paul Wheatley-Price and
Dr. Vishal Navani
